Longboard Pharmaceuticals, Inc. (LBPH)
| Market Cap | 2.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.34M |
| Shares Out | 39.05M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,798 |
| Open | 59.98 |
| Previous Close | 59.98 |
| Day's Range | 59.98 - 59.98 |
| 52-Week Range | 3.82 - 60.03 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 52.29 (-12.82%) |
| Earnings Date | Nov 7, 2024 |
About LBPH
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LBPH stock is "Buy." The 12-month stock price forecast is $52.29, which is a decrease of -12.82% from the latest price.
News
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharma...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning th...
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.8% on Monday.
S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise
The S&P 500 rose to a new record high of 5,859 on Monday ahead of key corporate earnings later this week. At the time of writing, the S&P 500 index was 0.8% higher than the previous close.
Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.
Longboard shareholders will be offered $60 per share in cash.
Lundbeck to buy Longboard Pharma in $2.6 billion deal
H Lundbeck A/S has agreed to buy US-based Longboard Pharmaceuticals in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday.
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbe...
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
My Strategy For Longboard Pharmaceuticals After Its Big Run
Longboard Pharma saw significant growth after the initial spike, with potential catalysts in the future. LBPH develops neurological medicines, with a strong pedigree from Arena Pharmaceuticals. Lead d...
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kev...
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...